- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04888195
Symptom Clusters in Hong Kong Chinese Children With Blood Cancer
12. april 2022 opdateret af: Dr Eva Ho, The Hong Kong Polytechnic University
Symptom Clusters in Hong Kong Chinese Children With Blood Cancer:: A Longitudinal Study
Pediatric blood cancer is the most common childhood malignancy.
Despite its survival has been substantially improved, children still have to pay a high price for numerous distressing symptoms resulted from chemotherapy.
Previous studies related to symptom experiences mainly focus on individual symptoms, rather than on multiple symptoms.
Understanding these distressing symptoms may help healthcare professionals to develop appropriate and effective interventions with the aims of alleviating symptom severity and thus promoting the child's psychosocial well-being and quality of life.
Studieoversigt
Detaljeret beskrivelse
A longitudinal study design will be conducted.
A sample of 120 patients age 5-17years, diagnosed with blood cancer but not yet receive any chemotherapy and able to communicate with Cantonese and read Chinese will be recruited in the pediatric oncology ward of Hong Kong Children's Hospital.
Undersøgelsestype
Observationel
Tilmelding (Forventet)
120
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Ka Wai Lam, PhD
- Telefonnummer: 27666420
- E-mail: kwkatlam@polyu.edu.hk
Studiesteder
-
-
Hong Kong,China
-
Hong Kong, Hong Kong,China, Hong Kong, 0000
- Rekruttering
- Ka Yan Ho
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
5 år til 17 år (Barn)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
We will recruit pediatric patients with blood cancer in the Hong Kong Children's Hospital
Beskrivelse
Inclusion Criteria:
- aged 5 - 17 years old
- diagnosed with blood cancer but not yet receive any chemotherapy
- able to communicate with Cantonese and read Chinese
Exclusion Criteria:
- who are scheduled to have concurrent cancer treatment
- with recurrent malignancy
- medical condition, or cognitive and learning problems in their medical records
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Questionnaire
This study aims to examine the cancer patient's symptom clusters and their changes over chemotherapy among pediatric patients with blood cancer in Hong Kong
|
Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy.
They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The therapy-related symptom checklist for children (TRSC-C)
Tidsramme: Before chemotherapy
|
For measuring the occurrence and severity of symptoms experienced by patients aged 5-17 when they undergo cancer treatment.
|
Before chemotherapy
|
|
The therapy-related symptom checklist for children (TRSC-C) at 1-week
Tidsramme: At 1-week follow-up
|
For measuring the occurrence and severity of symptoms experienced by patients aged 5-17 when they undergo cancer treatment.
|
At 1-week follow-up
|
|
The therapy-related symptom checklist for children (TRSC-C) at 1-month
Tidsramme: At 1-month follow-up
|
For measuring the occurrence and severity of symptoms experienced by patients aged 5-17 when they undergo cancer treatment.
|
At 1-month follow-up
|
|
The therapy-related symptom checklist for children (TRSC-C) at 3-month
Tidsramme: At 3-month follow-up
|
For measuring the occurrence and severity of symptoms experienced by patients aged 5-17 when they undergo cancer treatment.
|
At 3-month follow-up
|
|
The therapy-related symptom checklist for children (TRSC-C) at 6-month
Tidsramme: At 6-month follow-up
|
For measuring the occurrence and severity of symptoms experienced by patients aged 5-17 when they undergo cancer treatment.
|
At 6-month follow-up
|
|
Demographic sheet
Tidsramme: At baseline
|
collect the background information of our subjects, including their age, gender, educational attainment, parents' marital status and religious belief
|
At baseline
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Ka Yan Ho, phd, The Hong Kong Polytechnic University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. september 2021
Primær færdiggørelse (Forventet)
1. september 2024
Studieafslutning (Forventet)
1. september 2024
Datoer for studieregistrering
Først indsendt
3. maj 2021
Først indsendt, der opfyldte QC-kriterier
11. maj 2021
Først opslået (Faktiske)
17. maj 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. april 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. april 2022
Sidst verificeret
1. april 2022
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SC_Blood_cancer
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Barn
-
MedDay Pharmaceuticals SAEurofins OptimedAfsluttetSunde frivillige | Nedsat leverfunktion af moderat Child Pugh-kategoriFrankrig, Ungarn
-
RenJi HospitalAfsluttetBlodpladeantal/miltdiameterforhold | Child-Pugh klassificeringKina
-
Stanford UniversityNational Cancer Institute (NCI)AfsluttetTilbagevendende hepatocellulært karcinom | Child-Pugh klasse A | Child-Pugh klasse BForenede Stater, Japan
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsAfsluttetChild-Pugh klasse A | Stadium IIIA Hepatocellulært karcinom | Stadium IIIB hepatocellulært karcinom | Stadium IIIC hepatocellulært karcinom | Stadium IVA Hepatocellulært karcinom | Stadium IVB Hepatocellulært karcinom | Child-Pugh klasse BForenede Stater
-
Centre Hospitalier Universitaire DijonAfsluttetChild-Pugh A Hepatocellulært karcinomFrankrig
-
MindRank AI LtdIkke rekrutterer endnuHepatic Impairment (Mild and Moderate, Child-Pugh Class A and B) | Leverinsufficiens (MeSH ID: D048550)Kina
-
CatalYm GmbHRekrutteringChild-Pugh A Hepatocellulært karcinom | Ikke-operabelt eller metastatisk hepatocellulært karcinom | Svigt af førstelinjebehandling, der omfattede et godkendt anti-PD-(L)1-kompoundItalien, Tyskland
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCAfsluttetAvanceret hepatocellulært karcinom hos voksne | Child-Pugh klasse A | Trin III hepatocellulært karcinom | Stadium IIIA Hepatocellulært karcinom | Stadium IIIB hepatocellulært karcinom | Stadium IIIC hepatocellulært karcinom | Trin IV hepatocellulært karcinom | Stadium IVA Hepatocellulært karcinom | Stadium...Forenede Stater
-
AstraZenecaAfsluttetMavekræft | Avancerede solide maligniteter | Solid tumor | Child-Pugh A til B7 avanceret hepatocellulært karcinom | EGFR og/eller ROS Mutant NSCLC | LungemetastasekarcinomKorea, Republikken